Placental extract injections in the treatment of loss of hair in women.

Placental extract injections were used with success in case of loss of hair in women during the period following confinement and outside this period. The overall rate of improvement was 74%; total recovery occurred in 43% of cases. In postpartum cases the rate of improvement was 91%, recovery 64%. The results obtained in 65 cases are reported. A double-blind study is planned.

[Use of retroprogesterone]. / Verwendung der Retroprogesterone.

PIP: Clinical uses of retroprogesterones are briefly discussed. With the advent of retroprogesterones we have at our disposal gestagens with very few side effects, including virilization. In addition to the classical indications for oral progestins (menstrual irregularities during the menopause, hypermenorrhea, corpus luteum insufficiency, myoma), retroprogesterones may be used for menstrual irregularities in adolescence, for the maintenance of threatened pregnancy, and possibly as an ovulation stimulant.^ieng

[Hormone substitution in the female climacteric--goals, means, effects]. / Hormonsubstitution im Klimakterium der Frau--Ziele, Wege, Wirkungen.

Traditional beliefs about climacteric symptoms and widespread imaginations about unwanted effects of estrogens in the pill have long been interfering with the recommendation of an early onset of effective replacement therapy. The somatic symptoms of rush or genital atrophia have later on been classified as hard evidence to justify a therapy, much more than the predominant psychic signs occurring in the postmenopausal years as mental depressions, decrease or lacking of libido, nervousness, insomnia. Those signs were neglected as weaker indications responding even to a placebo treatment. The present knowledge understands somatic and psychosomatic signs as an entiety, both being accessible to hormonal replacement therapy. 85% of the postmenopausal signs can effectively be treated with hormones. What is now known about atherosclerosis, lipid metabolism and osteoporosis in ageing woman adds further justification to even the prophylactic use of estrogens. Natural estrogens administered orally, transdermally or parenterally are the means of choice. The dosage might be tailored on the relief of symptoms (and afterwards reduced to a mere maintaining dosage), or given in a fixed cyclic regimen. The treatment cycle will be three or four weeks, a progestogen should be added for the last 12-14 days. Only one estrogen-androgen combination has survived (Gynodian). The transdermal application (in three different concentrations) with administration twice a week is in progress. Indications and contraindications for transdermal estrogens are similar to estrogens administered orally.

[Coitus frequency and libido changes under oral contraception]. / Coitusfrequenz und Libidoveränderungen unter oraler Kontrazeption.

PIP: Coital frequency and libido were studied during oral contraception in 457 women who filled out daily forms for a total of 2584 cycles, averaging 1 year each. During pill cycles coital frequency was invariant. Frequency of coitus decreased to a minimum at age 30-35, then rose somewhat. It was lower on pill- and menstruation-free days. Frigid women had the same frequency as others of their age. 30% had a change in libido, 50% increased. 15.7% had decreased libido, which could be reversed in 80% of them by changing the pill formulation. 7/8 of those whose loss of libido could not be improved gave up oral contraception.^ieng

[Effect of placebo instead of a pause in the taking of ovulation inhibitors]. / Wirking von Placebo statt Pause bei Ovulationshemmern.

PIP: 2 preparations of a sequential oral contraceptive containing 11 tablets of .1 mg mestranol and 10 tablets of .1 mg mestranol and 2 mg chlormadinone were compared: 127 women took the pills with 7 placebos (Eunomin) for 848 cycles and 47 women took them without placebos (GC 527) for 267 cycles. 1 pregnancy occurred due to patient error. No differences were recorded in weight changes, bone symptoms, breakthrough bleeding, breast symptoms, or increased libido. Mucorrhea and constipation were more common with the placebos. The side effects of nausea, nervousness, headache, fatigue, and decreased libido were frequent with placebos. 19.8% discontinued Eunomin, while 23.4% stopped taking CG 527. 76.9% of the women on Eunomin and 65.2% of those on CG 527 did not have the side effects that they had experienced with previou s pills.^ieng